Ind-Swift Laboratories is manufacturing over 40 active pharmaceutical ingredients (APIs) which are supplied across 40 countries of the globe. The company has orders booked till next one year for its key APIs. Besides 40 APIs, the company has 8 APIs in its portfolio which are entering the regulated markets of US, EU and Japan which are expected to generate additional revenues on a sustained basis for the next 3-4 years.
Besides, the company has a pipeline of around 20 APIs which are part of long term growth strategy. These would be launched on expiry of patents which are scheduled from 2014 onwards. The products as of now are in seeding stage i.e. market promotion etc.
Further, the company has two API manufacturing facilities situated at Derabassi, Punjab and Jammu (J&K). The facility at Derabassi is spread across 40 acres of land with 19 manufacturing blocks for APIs, a Menthol facility and a captive power plant. Both the facilities of the company are running on three shifts.
Also, at the plant level, the company has undertaken initiatives to improve yields and reduce costs through process development and de-bottlenecking exercises, which is going to bring in significant improvement in efficiencies.
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. The company is engaged in manufacturing of Active Pharmaceutical Ingredients (API).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1517.90 |
Dr. Reddys Lab | 6362.00 |
Cipla | 1478.90 |
Zydus Lifesciences | 1066.95 |
Lupin | 1614.95 |
View more.. |